Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 166

Similar articles for PubMed (Select 21508120)

1.

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.

Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME, Maris MB, Laport GG, Chauncey TR, Lange T, Langston AA, Storer B, Georges GE.

Haematologica. 2011 Aug;96(8):1113-20. doi: 10.3324/haematol.2011.040261. Epub 2011 Apr 20.

2.
3.

Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission.

Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI.

Haematologica. 2009 Oct;94(10):1399-406. doi: 10.3324/haematol.2009.008649. Epub 2009 Jul 31.

4.

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.

Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ.

Blood. 2010 Jul 22;116(3):366-74. doi: 10.1182/blood-2010-01-264077. Epub 2010 Apr 19.

5.

Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.

Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM, Wong RM, Negrin RS, Blume KG, Forman SJ.

Blood. 2008 Aug 1;112(3):903-9. doi: 10.1182/blood-2008-03-143115. Epub 2008 Jun 2.

6.

Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.

Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernández-Avilés F, San Miguel J, Sierra J.

Haematologica. 2003 May;88(5):555-60.

7.

Myeloablative allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: significant roles of total body irradiation and chronic graft-versus-host disease.

Yanada M, Naoe T, Iida H, Sakamaki H, Sakura T, Kanamori H, Kodera Y, Okamoto S, Kanda Y, Sao H, Asai O, Nakai K, Maruta A, Kishi K, Furukawa T, Atsuta Y, Yamamoto K, Tanaka J, Takahashi S.

Bone Marrow Transplant. 2005 Nov;36(10):867-72.

PMID:
16113659
8.

[Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].

Cheng Z, Zhao L, Chen G, Wu D, Qiu H, Tang X, Fu C, Jin Z, Chen F, Xue S, Sun A.

Zhonghua Xue Ye Xue Za Zhi. 2014 Feb;35(2):114-9. doi: 10.3760/cma.j.issn.0253-2727.2014.02.012. Chinese.

9.

Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.

Chen H, Liu KY, Xu LP, Liu DH, Chen YH, Zhao XY, Han W, Zhang XH, Wang Y, Zhang YY, Qin YZ, Liu YR, Huang XJ.

J Hematol Oncol. 2012 Jun 8;5:29. doi: 10.1186/1756-8722-5-29.

10.

Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.

Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.

Haematologica. 2002 Jan;87(1):52-8.

11.

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Kim CC.

Leukemia. 2009 Oct;23(10):1763-70. doi: 10.1038/leu.2009.102. Epub 2009 May 14.

PMID:
19440217
13.

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

Eom KS, Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Kim YJ, Kim HJ, Min CK, Kim DW, Lee JW, Min WS, Park CW, Lee S.

Am J Hematol. 2013 Aug;88(8):634-41. doi: 10.1002/ajh.23465. Epub 2013 May 30.

PMID:
23620000
14.

The effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Zhang FH, Ling YW, Zhai X, Zhang Y, Huang F, Fan ZP, Zhou HS, Jiang QL, Sun J, Liu QF.

Hematology. 2013 May;18(3):151-7. doi: 10.1179/1607845412Y.0000000052. Epub 2013 Jan 29.

PMID:
23394269
15.

Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.

Shigematsu A, Kondo T, Yamamoto S, Sugita J, Onozawa M, Kahata K, Endo T, Shiratori S, Ota S, Obara M, Wakasa K, Takahata M, Takeda Y, Tanaka J, Hashino S, Nishio M, Koike T, Asaka M, Imamura M.

Biol Blood Marrow Transplant. 2008 May;14(5):568-75. doi: 10.1016/j.bbmt.2008.02.018.

16.

Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.

Gyurkocza B, Gutman J, Nemecek ER, Bar M, Milano F, Ramakrishnan A, Scott B, Fang M, Wood B, Pagel JM, Baumgart J, Delaney C, Maziarz RT, Sandmaier BM, Estey EH, Appelbaum FR, Storer BE, Deeg HJ.

Biol Blood Marrow Transplant. 2014 Apr;20(4):549-55. doi: 10.1016/j.bbmt.2014.01.009. Epub 2014 Jan 16.

17.

Haploidentical hematopoietic stem cell transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia: no difference in the high- and low-risk groups.

Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, Yan CH, Chen YH, Han W, Wang FR, Wang JZ, Liu KY, Huang XJ.

Int J Cancer. 2015 Apr 1;136(7):1697-707. doi: 10.1002/ijc.29146. Epub 2014 Sep 2.

PMID:
25138425
18.

Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen.

Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, Liu H, Heslop HE, Brenner MK, Krance RA.

Biol Blood Marrow Transplant. 2008 Nov;14(11):1245-52. doi: 10.1016/j.bbmt.2008.08.010.

19.

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.

Shimoni A, Kröger N, Zander AR, Rowe JM, Hardan I, Avigdor A, Yeshurun M, Ben-Bassat I, Nagler A.

Leukemia. 2003 Feb;17(2):290-7.

PMID:
12592325
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk